Presenifin 1 Glu318Gly polymorphism - Interpret with caution

被引:12
作者
Goldman, JS
Johnson, JK
McElligott, K
Suchowersky, O
Miller, BL
Van Deerlin, VM
机构
[1] Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94143 USA
[2] Alberta Childrens Prov Gen Hosp, Dept Med Genet, Calgary, AB T2T 5C7, Canada
[3] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[4] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA
关键词
D O I
10.1001/archneur.62.10.1624
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The significance of the presenilin 1 (PSEN1) Glu318Gly polymorphism has been described as either a causal mutation with reduced penetrance or a benign polymorphism. When this polymorphism is found in a symptomatic person with. a family history of dementia, counseling on recurrence risk becomes very problematic. Objective: To demonstrate that the PSEN1 Glu318Gly polymorphism should be interpreted cautiously. Design: Case histories of 2 patients with presenile dementia and family histories of dementia are described. The PSEN1 gene was sequenced in the patients and in 11 family members of patient 1. Results: Two patients with presenile dementia and personality change were found to carry the PSEN1 Glu318Gly polymorphism. The presence of the polymorphism was confirmed in several family members of patient 1 but was absent in 1 symptomatic relative. Conclusions: The Glu318Gly polymorphism may be associated with risk for neurodegenerative disease; however, in the cases described here, it did not appear to be a risk factor. Until there is consensus on whether it is associated with disease, families should be informed that the clinical significance of the polymorphism is uncertain.
引用
收藏
页码:1624 / 1627
页数:4
相关论文
共 15 条
[1]   Consensus recommendations for the postmortem diagnosis of Alzheimer's disease [J].
Ball, M ;
Braak, H ;
Coleman, P ;
Dickson, D ;
Duyckaerts, C ;
Gambetti, P ;
Hansen, L ;
Hyman, B ;
Jellinger, K ;
Markesbery, W ;
Perl, D ;
Powers, J ;
Price, J ;
Trojanowski, JQ ;
Wisniewski, H ;
Phelps, C ;
Khachaturian, Z .
NEUROBIOLOGY OF AGING, 1997, 18 (04) :S1-S2
[2]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[3]   Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population based study of presenile Alzheimer disease [J].
Cruts, M ;
van Duijn, CM ;
Backhovens, H ;
Van den Broeck, M ;
Wehnert, A ;
Serneels, S ;
Sherrington, R ;
Hutton, M ;
Hardy, J ;
St George-Hyslop, PH ;
Hofman, A ;
Van Broeckhoven, C .
HUMAN MOLECULAR GENETICS, 1998, 7 (01) :43-51
[4]  
Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO
[5]  
2-M
[6]   The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease [J].
Dermaut, B ;
Cruts, M ;
Slooter, AJC ;
Van Gestel, S ;
De Jonghe, C ;
Vanderstichele, H ;
Vanmechelen, E ;
Breteler, MM ;
Hofman, A ;
van Duijn, CM ;
Van Broeckhoven, C .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (01) :290-292
[7]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[8]   A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's disease [J].
Forsell, C ;
Froelich, S ;
Axelman, K ;
Vestling, M ;
Cowburn, RF ;
Lilius, L ;
Johnston, JA ;
Engvall, B ;
Johansson, K ;
Dahlkild, A ;
Ingelson, M ;
StGeorgeHyslop, PH ;
Lannfelt, L .
NEUROSCIENCE LETTERS, 1997, 234 (01) :3-6
[9]   Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease? [J].
Helisalmi, S ;
Hiltunen, M ;
Mannermaa, A ;
Koivisto, AM ;
Lehtovirta, M ;
Alafuzoff, I ;
Ryynänen, M ;
Soininen, H .
NEUROSCIENCE LETTERS, 2000, 278 (1-2) :65-68
[10]  
MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939